Download PDF
Semin Thromb Hemost 2012; 38(04): 305-321
DOI: 10.1055/s-0032-1311827
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Pathogenesis of the Antiphospholipid Syndrome

Rohan Willis
1   Antiphospholipid Standardization Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas
2   Department of Microbiology, University of the West Indies, Kingston, Jamaica
,
E. Nigel Harris
3   Office of the Vice Chancellor, University of the West Indies, Kingston, Jamaica
,
Silvia S. Pierangeli
1   Antiphospholipid Standardization Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas
› Author Affiliations
Further Information

Publication History

Publication Date:
17 April 2012 (online)

    Permissions and Reprints

Abstract

The presence of pathogenic antiphospholipid antibodies (aPL) is the characterizing feature of the antiphospholipid syndrome (APS), mediating the recurrent pregnancy loss and thrombosis typical of the disease, through their action on various antigenic targets. Despite the available knowledge regarding the mechanisms by which aPL induce a procoagulant phenotype in the vasculature and abnormal cellular proliferation and differentiation in placental tissues to cause the typical clinical features, these processes still remain incompletely understood. It is also known that inflammation serves as a necessary link between the observed procoagulant phenotype and actual thrombus development, and is an important mediator of the placental injury in APS patients. Even less well understood are the processes underlying the ontogeny of these pathogenic antibodies. This review seeks to highlight what is known about the mechanisms that contribute to the origin of pathogenic aPL and to the action of these antibodies on target antigens that produce the pathological features of APS. We will also examine the feasibility of classifying patients in clinical phenotypes related to underlying pathophysiological mechanisms, and how this could impact the management of patients with novel “targeted” therapeutic strategies.

Keywords

antiphospholipid antibodies - antiphospholipid syndrome - anticardiolipin antibodies - anti-β2-glycoprotein I antibodies - lupus anticoagulant
 

  • References

  • 1 Harris EN. Syndrome of the black swan. Br J Rheumatol 1987; 26 (5) 324-326
    CrossrefPubMedGoogle Scholar
  • 2 Wilson WA, Gharavi AE, Koike T , et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42 (7) 1309-1311
    CrossrefPubMedGoogle Scholar
  • 3 Miyakis S, Lockshin MD, Atsumi T , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (2) 295-306
    CrossrefPubMedGoogle Scholar
  • 4 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990; 87 (11) 4120-4124
    CrossrefPubMedGoogle Scholar
  • 5 Galli M, Comfurius P, Maassen C , et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335 (8705) 1544-1547
    CrossrefPubMedGoogle Scholar
  • 6 Amengual O, Atsumi T, Koike T. Antiprothombin antibodies and the diagnosis of antiphospholipid syndrome. Clin Immunol 2004; 112 (2) 144-149
    CrossrefPubMedGoogle Scholar
  • 7 Permpikul P, Rao LV, Rapaport SI. Functional and binding studies of the roles of prothrombin and beta 2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994; 83 (10) 2878-2892
    PubMedGoogle Scholar
  • 8 Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GRV. Thrombosis in SLE: striking association with the presence of circulating lupus anticoagulant. Br Med J (Clin Res Ed) 1983; 287: 1021-1023
    CrossrefPubMedGoogle Scholar
  • 9 Ginsburg KS, Liang MH, Newcomer L , et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117 (12) 997-1002
    CrossrefPubMedGoogle Scholar
  • 10 McClain MT, Arbuckle MR, Heinlen LD , et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004; 50 (4) 1226-1232
    CrossrefPubMedGoogle Scholar
  • 11 Tincani A, Balestrieri G, Danieli E , et al. Pregnancy complications of the antiphospholipid syndrome. Autoimmunity 2003; 36 (1) 27-32
    CrossrefPubMedGoogle Scholar
  • 12 Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346 (10) 752-763
    CrossrefPubMedGoogle Scholar
  • 13 Sailer T, Zaglami C, Kurz C , et al. Anti-beta(2)-glycoprotein-I antibodies are associated with pregnancy loss in women with the lupus anticoagulant. Thromb Haemost 2006; 95: 796-801
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. Lupus 2010; 19 (4) 419-423
    CrossrefPubMedGoogle Scholar
  • 15 Chen PP, Giles I. Antibodies to serine proteases in the antiphospholipid syndrome. Curr Rheumatol Rep 2010; 12 (1) 45-52
    CrossrefPubMedGoogle Scholar
  • 16 Meroni PL, Raschi E, Camera M , et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000; 15 (2) 237-240
    CrossrefPubMedGoogle Scholar
  • 17 Urbanus RT, Derksen RH, de Groot PG. Platelets and the antiphospholipid syndrome. Lupus 2008; 17 (10) 888-894
    CrossrefPubMedGoogle Scholar
  • 18 Nojima J, Suehisa E, Kuratsune H , et al. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus—possible association with thrombotic and thrombocytopenic complications. Thromb Haemost 1999; 81 (3) 436-441
    PubMedGoogle Scholar
  • 19 Krone KA, Allen KL, McCrae KR. Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep 2010; 12 (1) 53-57
    CrossrefPubMedGoogle Scholar
  • 20 Ames PR, Antinolfi I, Ciampa A , et al. Primary antiphospholipid syndrome: a low-grade auto-inflammatory disease?. Rheumatology (Oxford) 2008; 47 (12) 1832-1837
    CrossrefPubMedGoogle Scholar
  • 21 Abrahams VM. Mechanisms of antiphospholipid antibody-associated pregnancy complications. Thromb Res 2009; 124 (5) 521-525
    CrossrefPubMedGoogle Scholar
  • 22 Erkan D, Lockshin MD. Non-criteria manifestations of antiphospholipid syndrome. Lupus 2010; 19 (4) 424-427
    CrossrefPubMedGoogle Scholar
  • 23 D'Ippolito S, Di Simone N, Di Nicuolo F, Castellani R, Caruso A. Antiphospholipid antibodies: effects on trophoblast and endothelial cells. Am J Reprod Immunol 2007; 58 (2) 150-158
    CrossrefPubMedGoogle Scholar
  • 24 Di Simone N, Luigi MP, Marco D , et al. Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature. Ann N Y Acad Sci 2007; 1108: 505-514
    CrossrefPubMedGoogle Scholar
  • 25 Katsiari CG, Giavri I, Mitsikostas DD, Yiannopoulou KG, Sfikakis PP. Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation. Eur J Neurol 2011; 18 (4) 556-563
    CrossrefPubMedGoogle Scholar
  • 26 Gharavi AE, Pierangeli SS, Harris EN. Origin of antiphospholipid antibodies. Rheum Dis Clin North Am 2001; 27 (3) 551-563
    CrossrefPubMedGoogle Scholar
  • 27 Rauch J, Dieudé M, Subang R, Levine JS. The dual role of innate immunity in the antiphospholipid syndrome. Lupus 2010; 19 (4) 347-353
    CrossrefPubMedGoogle Scholar
  • 28 Lambrianides A, Carroll CJ, Pierangeli SS , et al. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol 2010; 184 (12) 6622-6628
    CrossrefPubMedGoogle Scholar
  • 29 Jiang H, Chess L. How the immune system achieves self-nonself discrimination during adaptive immunity. Adv Immunol 2009; 102: 95-133
    PubMedGoogle Scholar
  • 30 Hashimoto Y, Kawamura M, Ichikawa K , et al. Anticardiolipin antibodies in NZW x BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol 1992; 149 (3) 1063-1068
    PubMedGoogle Scholar
  • 31 Hang LM, Izui S, Dixon FJ. (NZW x BXSB)F1 hybrid. A model of acute lupus and coronary vascular disease with myocardial infarction. J Exp Med 1981; 154 (1) 216-221
    CrossrefPubMedGoogle Scholar
  • 32 Oyaizu N, Yasumizu R, Miyama-Inaba M , et al. (NZW x BXSB)F1 mouse. A new animal model of idiopathic thrombocytopenic purpura. J Exp Med 1988; 167 (6) 2017-2022
    CrossrefPubMedGoogle Scholar
  • 33 Kita Y, Sumida T, Iwamoto I, Yoshida S, Koike T. V gene analysis of anti-cardiolipin antibodies from (NZW x BXSB) F1 mice. Immunology 1994; 82 (3) 494-501
    PubMedGoogle Scholar
  • 34 Gharavi AE, Sammaritano LR, Wen J, Elkon KB. Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H). J Clin Invest 1992; 90 (3) 1105-1109
    CrossrefPubMedGoogle Scholar
  • 35 Gharavi AE, Pierangeli SS, Colden-Stanfield M, Liu XW, Espinola RG, Harris EN. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J Immunol 1999; 163 (5) 2922-2927
    PubMedGoogle Scholar
  • 36 Gharavi AE, Pierangeli SS, Gharavi EE , et al. Thrombogenic properties of antiphospholipid antibodies do not depend on their binding to beta2 glycoprotein 1 (beta2GP1) alone. Lupus 1998; 7 (5) 341-346
    CrossrefPubMedGoogle Scholar
  • 37 Gharavi EE, Chaimovich H, Cucurull E , et al. Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides. Lupus 1999; 8 (6) 449-455
    CrossrefPubMedGoogle Scholar
  • 38 Gharavi AE, Pierangeli SS, Espinola RG, Liu X, Colden-Stanfield M, Harris EN. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum 2002; 46 (2) 545-552
    CrossrefPubMedGoogle Scholar
  • 39 Gharavi AE, Vega-Ostertag M, Espinola RG , et al. Intrauterine fetal death in mice caused by cytomegalovirus-derived peptide induced aPL antibodies. Lupus 2004; 13 (1) 17-23
    CrossrefPubMedGoogle Scholar
  • 40 Blank M, Krause I, Fridkin M , et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002; 109 (6) 797-804
    PubMedGoogle Scholar
  • 41 Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002; 31 (4) 256-263
    CrossrefPubMedGoogle Scholar
  • 42 Sène D, Piette JC, Cacoub P. [Antiphospholipid antibodies, antiphospholipid syndrome and viral infections]. Rev Med Interne 2009; 30 (2) 135-141
    CrossrefPubMedGoogle Scholar
  • 43 Van O S GM, Meijers JC, Agar C , et al. Induction of anti-β2 -glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes. J Thromb Haemost 2011; 9 (12) 2447-2456
    CrossrefPubMedGoogle Scholar
  • 44 Passam FH, Giannakopoulos B, Mirarabshahi P, Krilis SA. Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I. J Thromb Haemost 2011; 9 (1) 275-282
    PubMedGoogle Scholar
  • 45 Aguilar-Valenzuela R, Nickerson K, Romay-Penabad Z , et al. Involvement of TLR7 and TLR9 in the production of antiphospholipid antibodies. Arthritis Rheum 2011; 63 (10) s281 (abstract 723)
    PubMedGoogle Scholar
  • 46 Papalardo E, Romay-Penabad Z, Christadoss P, Pierangeli S. Induction of pathogenic antiphospholipid antibodies in vivo are dependent on expression of MHC-II genes. Lupus 2010; 19: 496 (abstract)
    CrossrefPubMedGoogle Scholar
  • 47 Dagenais P, Urowitz MB, Gladman DD, Norman CS. A family study of the antiphospholipid syndrome associated with other autoimmune diseases. J Rheumatol 1992; 19 (9) 1393-1396
    PubMedGoogle Scholar
  • 48 Asherson RA, Doherty DG, Vergani D, Khamashta MA, Hughes GR. Major histocompatibility complex associations with primary antiphospholipid syndrome. Arthritis Rheum 1992; 35 (1) 124-125
    CrossrefPubMedGoogle Scholar
  • 49 Caliz R, Atsumi T, Kondeatis E , et al. HLA class II gene polymorphisms in antiphospholipid syndrome: haplotype analysis in 83 Caucasoid patients. Rheumatology (Oxford) 2001; 40 (1) 31-36
    CrossrefPubMedGoogle Scholar
  • 50 Galeazzi M, Sebastiani GD, Tincani A , et al. HLA class II alleles associations of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus 2000; 9 (1) 47-55
    CrossrefPubMedGoogle Scholar
  • 51 Wilson WA, Perez MC, Michalski JP, Armatis PE. Cardiolipin antibodies and null alleles of C4 in black Americans with systemic lupus erythematosus. J Rheumatol 1988; 15 (12) 1768-1772
    PubMedGoogle Scholar
  • 52 Hirose N, Williams R, Alberts AR , et al. A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome. Arthritis Rheum 1999; 42 (8) 1655-1661
    CrossrefPubMedGoogle Scholar
  • 53 Pierangeli SS, Barker JH, Stikovac D , et al. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemost 1994; 71 (5) 670-674
    Article in Thieme ConnectPubMedGoogle Scholar
  • 54 Stockmans F, Deckmyn H, Gruwez J, Vermylen J, Acland R. Continuous quantitative monitoring of mural, platelet-dependent, thrombus kinetics in the crushed rat femoral vein. Thromb Haemost 1991; 65 (4) 425-431
    PubMedGoogle Scholar
  • 55 Barker JH, Gu JM, Anderson GL , et al. The effects of heparin and dietary fish oil on embolic events and the microcirculation downstream from a small-artery repair. Plast Reconstr Surg 1993; 91 (2) 335-343
    CrossrefPubMedGoogle Scholar
  • 56 Pierangeli SS, Liu XW, Barker JH, Anderson G, Harris EN. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 1995; 74 (5) 1361-1367
    PubMedGoogle Scholar
  • 57 Olee T, Pierangeli SS, Handley HH , et al. Generation and characterization of monoclonal IgG anticardiolipin antibodies from a patient with the antiphospholipid syndrome. Proc Natl Acad Sci U S A 1996; 93: 8606-8611
    CrossrefPubMedGoogle Scholar
  • 58 Pierangeli SS, Liu SW, Anderson G, Barker JH, Harris EN. Thrombogenic properties of murine anti-cardiolipin antibodies induced by β 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Circulation 1996; 94 (7) 1746-1751
    CrossrefPubMedGoogle Scholar
  • 59 Jankowski M, Vreys I, Wittevrongel C , et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003; 101 (1) 157-162
    CrossrefPubMedGoogle Scholar
  • 60 Fischetti F, Durigutto P, Pellis V , et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106 (7) 2340-2346
    CrossrefPubMedGoogle Scholar
  • 61 Arad A, Proulle V, Furie RA, Furie BC, Furie B. β2-glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood 2011; 117 (12) 3453-3459
    CrossrefPubMedGoogle Scholar
  • 62 Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999; 99 (15) 1997-2002
    CrossrefPubMedGoogle Scholar
  • 63 Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001; 88 (2) 245-250
    CrossrefPubMedGoogle Scholar
  • 64 Pierangeli SS, Liu X, Espinola R , et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000; 84 (3) 388-395
    PubMedGoogle Scholar
  • 65 Aron AL, Cuellar ML, Brey RL , et al. Early onset of autoimmunity in MRL/++ mice following immunization with beta 2 glycoprotein I. Clin Exp Immunol 1995; 101 (1) 78-81
    PubMedGoogle Scholar
  • 66 Branch DW, Dudley DJ, Mitchell MD , et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990; 163 (1 Pt 1) 210-216
    CrossrefPubMedGoogle Scholar
  • 67 Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M, Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest 1992; 89 (5) 1558-1563
    CrossrefPubMedGoogle Scholar
  • 68 Fishman P, Falach-Vaknine E, Zigelman R , et al. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest 1993; 91 (4) 1834-1837
    CrossrefPubMedGoogle Scholar
  • 69 Holers VM, Girardi G, Mo L , et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195 (2) 211-220
    CrossrefPubMedGoogle Scholar
  • 70 Girardi G, Berman J, Redecha P , et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112 (11) 1644-1654
    CrossrefPubMedGoogle Scholar
  • 71 Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10 (11) 1222-1226
    CrossrefPubMedGoogle Scholar
  • 72 Simantov R, Lo SK, Gharavi A, Sammaritano LR, Salmon JE, Silverstein RL. Antiphospholipid antibodies activate vascular endothelial cells. Lupus 1996; 5 (5) 440-441
    PubMedGoogle Scholar
  • 73 Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994; 153 (3) 1328-1332
    PubMedGoogle Scholar
  • 74 Reverter JC, Tàssies D, Font J , et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 1998; 41 (8) 1420-1427
    CrossrefPubMedGoogle Scholar
  • 75 Forastiero R, Martinuzzo M, Carreras LO, Maclouf J. Anti-beta2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. Thromb Haemost 1998; 79 (1) 42-45
    PubMedGoogle Scholar
  • 76 Lellouche F, Martinuzzo M, Said P, Maclouf J, Carreras LO. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 1991; 78 (11) 2894-2899
    PubMedGoogle Scholar
  • 77 Khamashta MA, Harris EN, Gharavi AE , et al. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 1988; 47 (10) 849-854
    CrossrefPubMedGoogle Scholar
  • 78 Lutters BC, Derksen RH, Tekelenburg WL, Lenting PJ, Arnout J, de Groot PG. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem 2003; 278 (36) 33831-33838
    CrossrefPubMedGoogle Scholar
  • 79 Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002; 87 (3) 518-522
    PubMedGoogle Scholar
  • 80 Pierangeli SS, Vega-Ostertag M, Harris EN. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res 2004; 114 (5–6) 467-476
    CrossrefPubMedGoogle Scholar
  • 81 Shi T, Giannakopoulos B, Yan X , et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 2006; 54 (8) 2558-2567
    CrossrefPubMedGoogle Scholar
  • 82 Urbanus RT, Pennings MT, Derksen RH, de Groot PG. Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibalpha and apolipoprotein E receptor 2′. J Thromb Haemost 2008; 6 (8) 1405-1412
    CrossrefPubMedGoogle Scholar
  • 83 Sikara MP, Routsias JG, Samiotaki M, Panayotou G, Moutsopoulos HM, Vlachoyiannopoulos PG. beta2 Glycoprotein I (beta2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. Blood 2010; 115 (3) 713-723
    CrossrefPubMedGoogle Scholar
  • 84 Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79 (2) 276-281
    PubMedGoogle Scholar
  • 85 Alijotas-Reig J, Palacio-Garcia C, Vilardell-Tarres M. Circulating microparticles, lupus anticoagulant and recurrent miscarriages. Eur J Obstet Gynecol Reprod Biol 2009; 145 (1) 22-26
    CrossrefPubMedGoogle Scholar
  • 86 Cuadrado MJ, Buendía P, Velasco F , et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost 2006; 4 (11) 2461-2469
    CrossrefPubMedGoogle Scholar
  • 87 Lopez-Pedrera C, Perez-Sandrez C, Ruiz-Limon P , et al. Mitochondrial dysfunction in monocytes from antiphospholipid sundrome patients: implications in the pathogenesis of the disease and effects of coenzyme treatment. Arthritis Rheum 2011; 63 (10) s282 (abstract 725)
    PubMedGoogle Scholar
  • 88 Vega-Ostertag ME, Ferrara DE, Romay-Penabad Z , et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost 2007; 5 (9) 1828-1834
    CrossrefPubMedGoogle Scholar
  • 89 López-Pedrera C, Buendía P, Cuadrado MJ , et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006; 54 (1) 301-311
    CrossrefPubMedGoogle Scholar
  • 90 Romay-Penabad Z, Carrera-Marin AL, Mackman N, Pierangeli S. Pathogenic effects of antiphospholipid antibodies are ameliorated in tissue factor deficient mice. Arthritis Rheum 2011; 63 (10) s5 (abstract 13)
    PubMedGoogle Scholar
  • 91 Romay-Penabad Z, Montiel-Manzano MG, Shilagard T , et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 2009; 114 (14) 3074-3083
    CrossrefPubMedGoogle Scholar
  • 92 Zhang J, McCrae KR. Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood 2005; 105 (5) 1964-1969
    CrossrefPubMedGoogle Scholar
  • 93 Raschi E, Testoni C, Bosisio D , et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101 (9) 3495-3500
    CrossrefPubMedGoogle Scholar
  • 94 Pierangeli SS, Vega-Ostertag ME, Raschi E , et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis 2007; 66 (10) 1327-1333
    CrossrefPubMedGoogle Scholar
  • 95 Sorice M, Longo A, Capozzi A , et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007; 56 (8) 2687-2697
    CrossrefPubMedGoogle Scholar
  • 96 Allen KL, Fonseca FV, Betapudi V, Willard B, Zhang J, McCrae KR. A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies. Blood 2012; 119: 884-893
    CrossrefPubMedGoogle Scholar
  • 97 Döring Y, Hurst J, Lorenz M , et al. Human antiphospholipid antibodies induce TNFalpha in monocytes via toll-like receptor 8. Immunobiology 2010; 215 (3) 230-241
    CrossrefPubMedGoogle Scholar
  • 98 Hurst J, Prinz N, Lorenz M , et al. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells. Immunobiology 2009; 214 (8) 683-691
    CrossrefPubMedGoogle Scholar
  • 99 Prinz N, Clemens N, Strand D , et al. Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells. Blood 2011; 118 (8) 2322-2332
    CrossrefPubMedGoogle Scholar
  • 100 Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol 2006; 7 (1) 49-56
    CrossrefPubMedGoogle Scholar
  • 101 Raschi E, Broggini V, Grossi C, Borghi MO, Pierangeli SS, Meroni PL. Mechanisms of action of antiphospholipid antibodies. In: Cervera R, Asherson R, Khamashta M, Reverter JC, eds. Handbook of Systemic Autoimmune Diseases. Antiphospholipid Syndrome in Systemic Autoimmune Disease. Oxford, UK: Elsevier; 2009. 10. 55-67
    CrossrefGoogle Scholar
  • 102 Romay-Penabad Z, Aguilar-Valenzuela R, Urbanus RT , et al. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood 2011; 117 (4) 1408-1414
    CrossrefPubMedGoogle Scholar
  • 103 Zhao Y, Rumold R, Zhu M , et al. An IgG antiprothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times. Arthritis Rheum 1999; 42 (10) 2132-2138
    CrossrefPubMedGoogle Scholar
  • 104 Vega-Ostertag M, Liu X, Kwan-Ki H, Chen P, Pierangeli S. A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells. Br J Haematol 2006; 135 (2) 214-219
    CrossrefPubMedGoogle Scholar
  • 105 Atsumi T, Ieko M, Bertolaccini ML , et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000; 43 (9) 1982-1993
    CrossrefPubMedGoogle Scholar
  • 106 Hwang KK, Grossman JM, Visvanathan S , et al. Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 2001; 167 (12) 7192-7198
    CrossrefPubMedGoogle Scholar
  • 107 Escolar G, Font J, Reverter JC , et al. Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation. Studies in a perfusion system. Arterioscler Thromb 1992; 12 (2) 196-200
    CrossrefPubMedGoogle Scholar
  • 108 Yang YH, Chien D, Wu M , et al. Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. J Immunol 2009; 182 (3) 1674-1680
    PubMedGoogle Scholar
  • 109 Yang YH, Hwang KK, FitzGerald J , et al. Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin. J Immunol 2006; 177 (11) 8219-8225
    PubMedGoogle Scholar
  • 110 Griffin JH, Fernández JA, Gale AJ, Mosnier LO. Activated protein C. J Thromb Haemost 2007; 5 (1) 73-80
    CrossrefPubMedGoogle Scholar
  • 111 Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989; 74 (7) 2426-2432
    CrossrefPubMedGoogle Scholar
  • 112 Hwang KK, Yang CD, Yan W, Grossman JM, Hahn BH, Chen PP. A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C. Arthritis Rheum 2003; 48 (6) 1622-1630
    CrossrefPubMedGoogle Scholar
  • 113 Chamley LW, McKay EJ, Pattison NS. Inhibition of heparin/antithrombin III cofactor activity by anticardiolipin antibodies: a mechanism for thrombosis. Thromb Res 1993; 71 (2) 103-111
    CrossrefPubMedGoogle Scholar
  • 114 Yang CD, Hwang KK, Yan W , et al. Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004; 172 (9) 5765-5773
    PubMedGoogle Scholar
  • 115 Kolev K, Gombás J, Váradi B , et al. Immunoglobulin G from patients with antiphospholipid syndrome impairs the fibrin dissolution with plasmin. Thromb Haemost 2002; 87 (3) 502-508
    PubMedGoogle Scholar
  • 116 Lu CS, Horizon AA, Hwang KK , et al. Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. Arthritis Rheum 2005; 52 (12) 4018-4027
    CrossrefPubMedGoogle Scholar
  • 117 Cugno M, Cabibbe M, Galli M , et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood 2004; 103 (6) 2121-2126
    CrossrefPubMedGoogle Scholar
  • 118 Ames PR, Tommasino C, Iannaccone L, Brillante M, Cimino R, Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies—a crucial role for acquired free protein S deficiency. Thromb Haemost 1996; 76 (2) 190-194
    PubMedGoogle Scholar
  • 119 Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem 1994; 269 (33) 21198-21203
    PubMedGoogle Scholar
  • 120 Ao W, Zheng H, Chen XW, Shen Y, Yang CD. Anti-annexin II antibody is associated with thrombosis and/or pregnancy morbidity in antiphospholipid syndrome and systemic lupus erythematosus with thrombosis. Rheumatol Int 2011; 31 (7) 865-869
    CrossrefPubMedGoogle Scholar
  • 121 Cesarman-Maus G, Ríos-Luna NP, Deora AB , et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 2006; 107 (11) 4375-4382
    CrossrefPubMedGoogle Scholar
  • 122 Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 52 (7) 2120-2124
    CrossrefPubMedGoogle Scholar
  • 123 Romay-Penabad Z, Liu XX, Montiel-Manzano G, Papalardo De Martínez E, Pierangeli SS. C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. Ann N Y Acad Sci 2007; 1108: 554-566
    CrossrefPubMedGoogle Scholar
  • 124 Carrera-Marin AL, Romay-Penabad Z, Qu HC , et al. A C5a Receptor Antagonist Ameliorates In Vivo Effects of Antiphospholipid Antibodies. Arthritis Rheum 2009; 60: s767 (abstract)
    PubMedGoogle Scholar
  • 125 Carrera-Marin AL, Aguilar-Valenzuela R, Romay-Penabad Z , et al. Involvement of C6 and the MAC on in vivo antiphospholipid-mediated pathogenic effects. Lupus 2010; 19: 507 (abstract)
    PubMedGoogle Scholar
  • 126 Carrera-Marin AL, Romay-Penabad Z, Machin S, Cohen H, Pierangeli S. C5 inhibitor rEV576 ameliorates in vivo effects of antiphospholipid antibodies. Arthritis Rheum 2011; 63 (10) s5 (abstract 12)
    PubMedGoogle Scholar
  • 127 Oku K, Atsumi T, Bohgaki M , et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009; 68 (6) 1030-1035
    CrossrefPubMedGoogle Scholar
  • 128 De Wolf F, Carreras LO, Moerman P, Vermylen J, Van Assche A, Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol 1982; 142 (7) 829-834
    CrossrefPubMedGoogle Scholar
  • 129 Peaceman AM, Rehnberg KA. The effect of immunoglobulin G fractions from patients with lupus anticoagulant on placental prostacyclin and thromboxane production. Am J Obstet Gynecol 1993; 169 (6) 1403-1406
    PubMedGoogle Scholar
  • 130 Hanly JG, Gladman DD, Rose TH, Laskin CA, Urowitz MB. Lupus pregnancy. A prospective study of placental changes. Arthritis Rheum 1988; 31 (3) 358-366
    CrossrefPubMedGoogle Scholar
  • 131 Nayar R, Lage JM. Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Hum Pathol 1996; 27 (2) 201-206
    CrossrefPubMedGoogle Scholar
  • 132 Krikun G, Lockwood CJ, Wu XX , et al. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation. Placenta 1994; 15 (6) 601-612
    CrossrefPubMedGoogle Scholar
  • 133 Rand JH, Wu XX, Guller S , et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994; 171 (6) 1566-1572
    PubMedGoogle Scholar
  • 134 Rand JH, Wu XX, Guller S, Scher J, Andree HA, Lockwood CJ. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am J Obstet Gynecol 1997; 177 (4) 918-923
    CrossrefPubMedGoogle Scholar
  • 135 Wang X, Campos B, Kaetzel MA, Dedman JR. Annexin V is critical in the maintenance of murine placental integrity. Am J Obstet Gynecol 1999; 180 (4) 1008-1016
    CrossrefPubMedGoogle Scholar
  • 136 Nojima J, Kuratsune H, Suehisa E , et al. Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 2001; 47 (6) 1008-1015
    PubMedGoogle Scholar
  • 137 Donohoe S, Kingdom JC, Mackie IJ , et al. Ontogeny of beta 2 glycoprotein I and annexin V in villous placenta of normal and antiphospholipid syndrome pregnancies. Thromb Haemost 2000; 84 (1) 32-38
    PubMedGoogle Scholar
  • 138 Out HJ, Kooijman CD, Bruinse HW, Derksen RH. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 1991; 41 (3) 179-186
    CrossrefPubMedGoogle Scholar
  • 139 McIntyre JA. Immune recognition at the maternal-fetal interface: overview. Am J Reprod Immunol 1992; 28 (3–4) 127-131
    PubMedGoogle Scholar
  • 140 Castellucci M, De Matteis R, Meisser A , et al. Leptin modulates extracellular matrix molecules and metalloproteinases: possible implications for trophoblast invasion. Mol Hum Reprod 2000; 6 (10) 951-958
    CrossrefPubMedGoogle Scholar
  • 141 Di Simone N, Meroni PL, de Papa N , et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum 2000; 43 (1) 140-150
    CrossrefPubMedGoogle Scholar
  • 142 Katsuragawa H, Kanzaki H, Inoue T, Hirano T, Mori T, Rote NS. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion. Biol Reprod 1997; 56 (1) 50-58
    CrossrefPubMedGoogle Scholar
  • 143 Adler RR, Ng AK, Rote NS. Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR. Biol Reprod 1995; 53 (4) 905-910
    CrossrefPubMedGoogle Scholar
  • 144 Chamley LW, Duncalf AM, Mitchell MD, Johnson PM. Action of anticardiolipin and antibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet 1998; 352 (9133) 1037-1038
    CrossrefPubMedGoogle Scholar
  • 145 Rote NS, Vogt E, DeVere G, Obringer AR, Ng AK. The role of placental trophoblast in the pathophysiology of the antiphospholipid antibody syndrome. Am J Reprod Immunol 1998; 39 (2) 125-136
    CrossrefPubMedGoogle Scholar
  • 146 Di Simone N, Castellani R, Caliandro D, Caruso A. Antiphospholid antibodies regulate the expression of trophoblast cell adhesion molecules. Fertil Steril 2002; 77 (4) 805-811
    CrossrefPubMedGoogle Scholar
  • 147 Di Simone N, Marana R, Castellani R , et al. Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. Arthritis Rheum 2010; 62 (5) 1504-1512
    CrossrefPubMedGoogle Scholar
  • 148 Ornoy A, Yacobi S, Matalon ST , et al. The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture. Lupus 2003; 12 (7) 573-578
    CrossrefPubMedGoogle Scholar
  • 149 Matalon ST, Shoenfeld Y, Blank M, Yacobi S, von Landenberg P, Ornoy A. Antiphosphatidylserine antibodies affect rat yolk sacs in culture: a mechanism for fetal loss in antiphospholipid syndrome. Am J Reprod Immunol 2004; 51 (2) 144-151
    CrossrefPubMedGoogle Scholar
  • 150 di Simone N, Castellani R, Raschi E, Borghi MO, Meroni PL, Caruso A. Anti-beta-2 glycoprotein I antibodies affect Bcl-2 and Bax trophoblast expression without evidence of apoptosis. Ann N Y Acad Sci 2006; 1069: 364-376
    CrossrefPubMedGoogle Scholar
  • 151 Borghi MO, Raschi E, Scurati S , et al. Effects of a toll-like receptor antagonist and anti-annexin A2 antibodies on binding and activation of decidual cells by anti-β2glycoprotein I antibodies. Clin Exp Rheumatol 2007; 2: 35
    PubMedGoogle Scholar
  • 152 Francis J, Rai R, Sebire NJ , et al. Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome. Mol Hum Reprod 2006; 12 (7) 435-442
    CrossrefPubMedGoogle Scholar
  • 153 Di Simone N, Di Nicuolo F, D'Ippolito S , et al. Antiphospholipid antibodies affect human endometrial angiogenesis. Biol Reprod 2010; 83 (2) 212-219
    CrossrefPubMedGoogle Scholar
  • 154 Riley JK, Nelson DM. Toll-like receptors in pregnancy disorders and placental dysfunction. Clin Rev Allergy Immunol 2010; 39: 185-193
    CrossrefPubMedGoogle Scholar
  • 155 Bogic LV, Ohira RH, Yamamoto SY, Okazaki KJ, Millar K, Bryant-Greenwood GD. Tissue plasminogen activator and its receptor in the human amnion, chorion, and decidua at preterm and term. Biol Reprod 1999; 60 (4) 1006-1012
    CrossrefPubMedGoogle Scholar
  • 156 Mulla MJ, Brosens JJ, Chamley LW , et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. Am J Reprod Immunol 2009; 62 (2) 96-111
    CrossrefPubMedGoogle Scholar
  • 157 Mulla MJ, Myrtolli K, Brosens JJ , et al. Antiphospholipid antibodies limit trophoblast migration by reducing IL-6 production and STAT3 activity. Am J Reprod Immunol 2010; 63 (5) 339-348
    CrossrefPubMedGoogle Scholar
  • 158 Chaouat G. The Th1/Th2 paradigm: still important in pregnancy?. Semin Immunopathol 2007; 29 (2) 95-113
    CrossrefPubMedGoogle Scholar
  • 159 Martinez de la Torre Y, Buracchi C, Borroni EM , et al. Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci U S A 2007; 104 (7) 2319-2324
    CrossrefPubMedGoogle Scholar
  • 160 Quigg RJ, Kozono Y, Berthiaume D , et al. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J Immunol 1998; 160 (9) 4553-4560
    PubMedGoogle Scholar
  • 161 Redecha P, Tilley R, Tencati M , et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007; 110 (7) 2423-2431
    CrossrefPubMedGoogle Scholar
  • 162 Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006; 203 (9) 2165-2175
    CrossrefPubMedGoogle Scholar
  • 163 Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007; 196 (2) 167.e1-167.e5
    CrossrefPubMedGoogle Scholar
  • 164 Cavazzana I, Manuela N, Irene C , et al. Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?. J Autoimmun 2007; 28 (2–3) 160-164
    CrossrefPubMedGoogle Scholar
  • 165 Stone S, Pijnenborg R, Vercruysse L , et al. The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta 2006; 27 (4–5) 457-467
    CrossrefPubMedGoogle Scholar
  • 166 Buyon JP, Garabet L, Kim M , et al. Favorable prognosis in a large, prospective multicenter study of lupus pregnancies. Arthritis Rheum 2011; 63 (10) s669 (abstract 1707)
    PubMedGoogle Scholar
  • 167 Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I , et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20 (2) 206-218
    CrossrefPubMedGoogle Scholar
  • 168 Edwards MH, Pierangeli SS, Liu X, Barker JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997; 96 (12) 4380-4384
    CrossrefPubMedGoogle Scholar
  • 169 Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009; 68 (2) 238-241
    CrossrefPubMedGoogle Scholar
  • 170 Ferrara DE, Liu X, Espinola RG , et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003; 48 (11) 3272-3279
    CrossrefPubMedGoogle Scholar
  • 171 Murthy V, Erkan D, Jajoria P , et al. Effects of fluvastatin on pro-inflammatory and pro-thrombotic markers in antiphospholipid antibody (aPL)-positive patients: preliminary results from an open-label prospective pilot study. Arthritis Rheum 2011; 63 (10) s283 (abstract 726)
    PubMedGoogle Scholar
  • 172 Erre GL, Pardini S, Faedda R, Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 2008; 17 (1) 50-55
    CrossrefPubMedGoogle Scholar
  • 173 Erkan D, Vega J, Ramon G, Kozora E, Lockshin MD. Rituximab in antiphospholipid syndrome (RITAPS)—a pilot open-label phase II prospective trial for non-criteria manifestations of antiphospholipid antibodies (aPL). Arthritis Rheum 2011; 63 (10) s283 (abstract 727)
    PubMedGoogle Scholar
  • 174 Zhou H, Wolberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004; 104 (8) 2353-2358
    CrossrefPubMedGoogle Scholar
  • 175 Simoncini S, Sapet C, Camoin-Jau L , et al. Role of reactive oxygen species and p38 MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome. Int Immunol 2005; 17 (4) 489-500
    CrossrefPubMedGoogle Scholar
  • 176 Ostertag MV, Liu X, Henderson V, Pierangeli SS. A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice. Lupus 2006; 15 (6) 358-365
    CrossrefPubMedGoogle Scholar
  • 177 Martinez de la Torre Y, Pregnolato F, D'Amelio F, Grossi C, Disimone N , et al. Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the β2 glycoprotein I phospholipid-binding site. Implications for human fetal loss. J Autoimmun 2011; 38: J209-J215
    PubMedGoogle Scholar
  • 178 Sebire NJ, Fox H, Backos M, Rai R, Paterson C, Regan L. Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod 2002; 17 (4) 1067-1071
    CrossrefPubMedGoogle Scholar
  • 179 Shamshirsaz AA, Paidas M, Krikun G. Preeclampsia, hypoxia, thrombosis, and inflammation. J Pregnancy 2012; 2012: 374047
    CrossrefPubMedGoogle Scholar
  • 180 Lambrianides A, Carroll C, Pericleous C , et al. Differential clinical manifestations of the antiphospholipid syndrome may be predicted by different intracellular signaling pathways. Arthritis Rheum 2007; 56 (S9) S533
    PubMedGoogle Scholar
  • 181 Carroll TY, Mulla MJ, Han CS , et al. Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin. Am J Reprod Immunol 2011; 66 (4) 286-296
    CrossrefPubMedGoogle Scholar